|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online February 4, 2009
doi: 10.1242/10.1242/jcs.031682
Cell Science at a Glance |
Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
* Author for correspondence (e-mail: Anthony_Letai{at}dfci.harvard.edu)
| Introduction |
|---|
|
|
|---|
|
Expression of Bcl-2 or other related anti-apoptotic proteins, including myeloid cell leukemia-1 (Mcl-1), Bcl-2-like 1 (Bcl-XL), Bcl-2-like 2 (Bcl-w) and Bcl-2-related protein A1 (Bfl-1), block cell death in response to many varieties of insult by preventing the activation and homo-oligomerization of both Bax and Bak. Anti-apoptotic proteins perform their anti-death function by sequestering BH3-only proteins or activated, monomeric Bax and Bak. Cells that survive continuous, permanent death signaling owing to the presence of Bcl-2 are dependent on Bcl-2 for their survival. It is known that certain cancer cells depend upon Bcl-2 and other anti-apoptotic proteins for survival. We have found that dependence on anti-apoptotic proteins can be identified in cancer cells using a strategy that we call BH3 profiling (see below and Box 1). In cancer cells that are dependent on Bcl-2, the Bcl-2 protein binds pro-apoptotic BH3-only proteins such as Bcl-2-interacting mediator of cell death (Bim). We describe such cells as being `primed for death'. Molecular therapies that are targeted to anti-apoptotic proteins such as Bcl-2 can induce apoptosis in primed cancer cells; one such Bcl-2 antagonist, Abbott (ABT)-737, has shown impressive success in killing leukemia and lymphoma cells (Table 1).
|
In this brief Cell Science at a Glance poster article, we discuss how proteins of the Bcl-2 family control the crucial event in the commitment to apoptosis – the permeabilization of the mitochondrial outer membrane. In addition, we discuss recently developed methods for probing how cancer cells manipulate members of the Bcl-2 family to block apoptosis. Understanding these principles is key to understanding how certain insults and derangements commit selected cells to death, but spare others.
| Box 1. The BH3 profiling technique BH3 profiling is a technique that uses BH3 domains of BH3-only proteins to apply a standardized death signal to mitochondria. This allows for the comparison of how readily different mitochondria, and hence cells, undergo apoptosis. Each anti-apoptotic protein of the Bcl-2 family has a distinct pattern of binding to certain BH3-only proteins. Peptides are designed using the amino-acid sequence (approximately 20 amino acids) of the corresponding BH3-only protein. Mitochondria are isolated from the cell line or patient sample. Peptides are incubated with the mitochondria and mitochondrial outer-membrane permeabilization (MOMP) is measured. The resulting pattern of peptides that do or do not cause MOMP is the readout of the assay. BH3 profiling can also distinguish among three classes of apoptotic block that are used by cancer cells to survive. A class A block indicates that functional activator BH3-only proteins are present at relatively low levels. In this case, the BH3-only protein activators Bid and Bim, but not any of the BH3-only protein sensitizer peptides, would cause MOMP. In a class B block, the pro-apoptotic proteins Bax and/or Bak are absent or not functional. In this case, none of the BH3-only peptides would cause MOMP as Bax and/or Bak are required for their effect. A class C block indicates that anti-apoptotic proteins are present and primed with BH3-only protein activators, or activated Bax or Bak. In this case, one can compare the pattern of the BH3-only sensitizer peptides that cause MOMP with the binding code for the specific anti-apoptotic proteins to determine which anti-apoptotic proteins are primarily responsible for maintaining survival.
|
| Members of the Bcl-2 family |
|---|
|
|
|---|
| Mitochondrial permeabilization |
|---|
|
|
|---|
One of the steps that is involved in the activation of Bax and Bak is a conformational change that exposes the N-terminus of the proteins, which is otherwise hidden in the inactive state (Yethon et al., 2003
). This activated conformation can be recognized by conformation-specific antibodies, such as 6A7, which is specific for Bax (Hsu and Youle, 1997
). Following activation, Bax and Bak form homo-oligomers that can be visualized via western blotting following chemical crosslinking (Wei et al., 2000
). Bax and Bak oligomers participate in forming pores in and cause permeabilization of the outer mitochondrial membrane, leading to the release of the contents of the mitochondrial intermembrane space, including cytochrome c and Smac, into the cytosol (Wang, 2001
). These contents drive the activation of caspases, which are proteases that cleave and disable crucial proteins throughout the cell.
| Bax and Bak activation |
|---|
|
|
|---|
According to the direct model of Bax and Bak activation, activator proteins (which include Bid, Bim and possibly others such as Puma and p53) directly interact with and induce conformational changes in Bax and Bak. Studies using full-length proteins, lipid membranes and real-time fluorescence resonance energy transfer (FRET) analyses has provided convincing evidence of such an interaction and for its role in membrane permeabilization (Lovell et al., 2008
). Anti-apoptotic proteins prevent death by binding and sequestering such pro-apoptotic activator BH3-only proteins, and also by binding any monomeric, activated Bax and Bak proteins that might be present. In this model, BH3-only proteins are further divided into activator and sensitizer categories (Letai et al., 2002
). Sensitizers cannot activate Bax and Bak directly, but can bind anti-apoptotic proteins and cause the release of activator BH3-only proteins, leading to activation of Bax and Bak. A prediction of this model is that the deletion of all activators would result in a profound block in apoptosis that is equivalent to the loss of Bax and Bak. By contrast, however, a combined knockout of Bid and Bim results in relatively minor defects in apoptosis (Willis et al., 2007
), but it is likely that additional factors other than Bid and Bim can act as activators. In fact, there are data that support the role of Puma, p53 and heat as activators of Bax and Bak (Chipuk et al., 2004
; Kim et al., 2006
; Pagliari et al., 2005
), and possibly others remain undiscovered. The important point is that the activation of Bax and Bak might be affected by factors outside of the Bcl-2 family of proteins. Very recent results have demonstrated a structure of a complex of the BH3 domain of Bim with Bax (Gavathiotis et al., 2008
). Surprisingly, the interaction takes place on the Bax surface distal from the hydrophobic pocket formed by the BH1, BH2 and BH3 domains. The analogous pocket is used by anti-apoptotic proteins to bind BH3 domains.
The gulf between the two models is not unbridgeable. As long as one is willing to accept that there are activated subsets of Bax and Bak that are required to kill, and that must be sequestered by anti-apoptotic proteins to maintain survival, a unifying model can be constructed. In this model, activated Bax and Bak are responsible for the permeabilization of membranes. They achieve the activated state either by interacting with activator proteins, by spontaneously activating, or via other unknown means. Anti-apoptotic proteins inhibit death by sequestering activator proteins or activated Bax and Bak. In addition to activating Bax and Bak (a property possessed by only a subset of BH3-only proteins), BH3-only proteins cause death by displacing activators and Bax and Bak from anti-apoptotic proteins, permitting progression of the death signal. This model is summarized in the poster accompanying this article.
| Specificity in the interaction between anti-apoptotic and BH3-only proteins |
|---|
|
|
|---|
| BH3 profiling |
|---|
|
|
|---|
| Future directions |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
Billen, L. P., Kokoski, C. L., Lovell, J. F., Leber, B. and Andrews, D. W. (2008). Bcl-XL inhibits membrane permeabilization by competing with Bax. PLoS Biol. 6, e147.[CrossRef][Medline]
Certo, M., Del Gaizo Moore, V., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S. A. and Letai, A. (2006). Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351-365.[CrossRef][Medline]
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M. and Huang, D. C. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17, 393-403.[CrossRef][Medline]
Cheng, E. H., Sheiko, T. V., Fisher, J. K., Craigen, W. J. and Korsmeyer, S. J. (2003). VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 301, 513-517.
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M. and Green, D. R. (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010-1014.
Chittenden, T., Flemington, C., Houghton, A. B., Ebb, R. G., Gallo, G. J., Elangovan, B., Chinnadurai, G. and Lutz, R. J. (1995). A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 14, 5589-5596.[Medline]
Danial, N. N. and Korsmeyer, S. J. (2004). Cell death: critical control points. Cell 116, 205-219.[CrossRef][Medline]
Del Gaizo Moore, V., Brown, J. R., Certo, M., Love, T. M., Novina, C. D. and Letai, A. (2007). Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 117, 112-121.[CrossRef][Medline]
Deng, J., Carlson, N., Takeyama, K., Dal Cin, P., Shipp, M. and Letai, A. (2007). BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12, 171-185.[CrossRef][Medline]
Fletcher, J. I., Meusburger, S., Hawkins, C. J., Riglar, D. T., Lee, E. F., Fairlie, W. D., Huang, D. C. and Adams, J. M. (2008). Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc. Natl. Acad. Sci. USA 105, 18081-18087.
Gavathiotis, E., Suzuki, M., Davis, M. L., Pitter, K., Bird, G. H., Katz, S. G., Tu, H. C., Kim, H., Cheng, E. H., Tjandra, N. et al. (2008). BAX activation is initiated at a novel interaction site. Nature 455, 1076-1081.[CrossRef][Medline]
Hengartner, M. O. and Horvitz, H. R. (1994). C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 76, 665-676.[CrossRef][Medline]
Hengartner, M. O., Ellis, R. E. and Horvitz, H. R. (1992). Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 356, 494-499.[CrossRef][Medline]
Hsu, Y. T. and Youle, R. J. (1997). Nonionic detergents induce dimerization among members of the Bcl-2 family. J. Biol. Chem. 272, 13829-13834.
Hsu, Y. T., Wolter, K. G. and Youle, R. J. (1997). Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc. Natl. Acad. Sci. USA 94, 3668-3672.
Kim, H., Rafiuddin-Shah, M., Tu, H. C., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J. and Cheng, E. H. (2006). Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8, 1348-1358.[CrossRef][Medline]
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P. and Craig, R. W. (1993). MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. USA 90, 3516-3520.
Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R. and Newmeyer, D. D. (2005). BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 17, 525-535.[CrossRef][Medline]
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S. and Korsmeyer, S. J. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183-192.[CrossRef][Medline]
Li, H., Zhu, H., Xu, C. J. and Yuan, J. (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501.[CrossRef][Medline]
Lindsten, T., Ross, A. J., King, A., Zong, W. X., Rathmell, J. C., Shiels, H. A., Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K. et al. (2000). The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell 6, 1389-1399.[CrossRef][Medline]
Lovell, J. F., Billen, L. P., Bindner, S., Shamas-Din, A., Fradin, C., Leber, B. and Andrews, D. W. (2008). Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135, 1074-1084.[CrossRef][Medline]
Nakano, K. and Vousden, K. H. (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683-694.[CrossRef][Medline]
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T. and Tanaka, N. (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053-1058.
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J. et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681.[CrossRef][Medline]
Opferman, J. T., Letai, A., Beard, C., Sorcinelli, M. D., Ong, C. C. and Korsmeyer, S. J. (2003). Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 671-676.[CrossRef][Medline]
Pagliari, L. J., Kuwana, T., Bonzon, C., Newmeyer, D. D., Tu, S., Beere, H. M. and Green, D. R. (2005). The multidomain proapoptotic molecules Bax and Bak are directly activated by heat. Proc. Natl. Acad. Sci. USA 102, 17975-17980.
Puthalakath, H., Huang, D. C., O'Reilly, L. A., King, S. M. and Strasser, A. (1999). The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell 3, 287-296.[CrossRef][Medline]
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P. et al. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428.
Wang, X. (2001). The expanding role of mitochondria in apoptosis. Genes Dev. 15, 2922-2933.
Wei, M. C., Lindsten, T., Mootha, V. K., Weiler, S., Gross, A., Ashiya, M., Thompson, C. B. and Korsmeyer, S. J. (2000). tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 14, 2060-2071.
Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B. and Korsmeyer, S. J. (2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730.
Willis, S. N., Fletcher, J. I., Kaufmann, T., van Delft, M. F., Chen, L., Czabotar, P. E., Ierino, H., Lee, E. F., Fairlie, W. D., Bouillet, P. et al. (2007). Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856-859.
Wolter, K. G., Hsu, Y. T., Smith, C. L., Nechushtan, A., Xi, X. G. and Youle, R. J. (1997). Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 139, 1281-1292.
Yethon, J. A., Epand, R. F., Leber, B., Epand, R. M. and Andrews, D. W. (2003). Interaction with a membrane surface triggers a reversible conformational change in Bax normally associated with induction of apoptosis. J. Biol. Chem. 278, 48935-48941.
Zha, J., Harada, H., Yang, E., Jockel, J. and Korsmeyer, S. J. (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87, 619-628.[CrossRef][Medline]
Zhong, Q., Gao, W., Du, F. and Wang, X. (2005). Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121, 1085-1095.[CrossRef][Medline]
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||